Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.52 |
| ▸ | ITGAV | P06756 | 19/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217610 | 0.94 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211540 | 0.93 | ITGB3 (0.46) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211451 | 0.93 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5HDAC3 | |
| SCHEMBL7217515 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7212704 | 0.90 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7217767 | 0.89 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211465 | 0.89 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7217733 | 0.87 | ITGB3 (0.40) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211463 | 0.86 | ITGB3 (0.41) | ITGB3ITGAVITGA2BITGB5HDAC3 | |
| SCHEMBL7216436 | 0.84 | ITGB3 (0.39) | ITGB3ITGAVITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885ITGA2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.